BeiGene Rises After Pricing US IPO at $24

Showing strong demand, BeiGene, a Beijing clinical-stage novel drug company, raised $158.4 million in its US IPO. The company priced the offering at the top of the expected range -- $24 per share -- and increased its size from 5.5 million ADSs to 6.6 million. In early trading, the company's stock rose $4.17 to $28.17, a 17% increase. The transaction is especially impressive in view of the early-2016 market turmoil, which prevented any companies from completing IPOs in the US during the month of January. More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //